Recursion Pharmaceuticals/RXRX
US$9.72
3.18%-
1D1W1MYTD1YMAX
About Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.
Ticker
RXRX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Christopher Gibson
Employees
500
Headquarters
Salt lake city, United States
Website
www.recursion.com
RXRX Metrics
BasicAdvanced
US$2.2B
Market cap
-
P/E ratio
-US$1.62
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
US$2.2B
52-week high
US$16.75
52-week low
US$4.97
Average daily volume
6.2M
Financial strength
Current ratio
4.648
Long term debt to equity
0.267
Total debt to equity
0.281
Management effectiveness
Return on assets (TTM)
-59.76%
Return on equity (TTM)
-85.19%
Return on investment (TTM)
-69.49%
Valuation
Price to revenue (TTM)
48.422
Price to book
5.577
Price to tangible book (TTM)
7.084
Growth
Revenue change (TTM)
-0.88%
Earnings per share change (TTM)
-17.33%
3-year revenue growth
124.07%
What the Analysts think about RXRX
Analyst Ratings
Majority rating from 7 analysts.
Price Targets
Average projection from 6 analysts.
High US$17.00
Low US$10.00
US$9.72
Current price
US$13.00
Average price target
RXRX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
US$14M
26.85%
Net income
-US$91M
-1.72%
Profit margin
-666.42%
-22.53%
RXRX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-US$0.38
-US$0.43
-US$0.42
-US$0.39
-
Expected
-US$0.37
-US$0.39
-US$0.45
-US$0.42
-US$0.41
Surprise
1.53%
11.69%
-6.41%
-7.87%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Upcoming events
FAQs
What’s the current market cap for Recursion Pharmaceuticals stock?
Recursion Pharmaceuticals (RXRX) has a market cap of $2.2B as of May 20, 2024.
What is the P/E ratio for Recursion Pharmaceuticals stock?
The price to earnings (P/E) ratio for Recursion Pharmaceuticals (RXRX) stock is 0 as of May 20, 2024.
Does Recursion Pharmaceuticals stock pay dividends?
No, Recursion Pharmaceuticals (RXRX) stock does not pay dividends to its shareholders as of May 20, 2024.
When is the next Recursion Pharmaceuticals dividend payment date?
Recursion Pharmaceuticals (RXRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Recursion Pharmaceuticals?
Recursion Pharmaceuticals (RXRX) does not currently have a Beta indicator.
What is the Recursion Pharmaceuticals stock price target?
The target price for Recursion Pharmaceuticals (RXRX) stock is $13, which is 33.2% above the current price of $9.76. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.
Buy or sell Recursion Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.